BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 8772215)

  • 1. Subcutaneous low-molecular-weight heparin fragmin versus intravenous unfractionated heparin in the treatment of acute non massive pulmonary embolism: an open randomized pilot study.
    Meyer G; Brenot F; Pacouret G; Simonneau G; Gillet Juvin K; Charbonnier B; Sors H
    Thromb Haemost; 1995 Dec; 74(6):1432-5. PubMed ID: 8772215
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of subcutaneous unfractionated heparin with a low molecular weight heparin (Fragmin) in patients with venous thromboembolism and contraindications to coumarin.
    Monreal M; Lafoz E; Olive A; del Rio L; Vedia C
    Thromb Haemost; 1994 Jan; 71(1):7-11. PubMed ID: 8165649
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low molecular weight heparin (dalteparin) is equally effective as unfractionated heparin in reducing coagulation activity and perfusion abnormalities during the early treatment of pulmonary embolism.
    Schutgens RE; Esseboom EU; Snijder RJ; Haas FJ; Verzijlbergen F; Nieuwenhuis HK; Lisman T; Biesma DH
    J Lab Clin Med; 2004 Aug; 144(2):100-7. PubMed ID: 15322504
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outpatient treatment of pulmonary embolism with dalteparin.
    Kovacs MJ; Anderson D; Morrow B; Gray L; Touchie D; Wells PS
    Thromb Haemost; 2000 Feb; 83(2):209-11. PubMed ID: 10739374
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A multicenter randomized double-blind study of enoxaparin compared with unfractionated heparin in the prevention of venous thromboembolic disease in elderly in-patients bedridden for an acute medical illness. The Enoxaparin in Medicine Study Group.
    Bergmann JF; Neuhart E
    Thromb Haemost; 1996 Oct; 76(4):529-34. PubMed ID: 8902991
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjusted versus fixed doses of the low-molecular-weight heparin fragmin in the treatment of deep vein thrombosis. Fragmin-Study Group.
    Alhenc-Gelas M; Jestin-Le Guernic C; Vitoux JF; Kher A; Aiach M; Fiessinger JN
    Thromb Haemost; 1994 Jun; 71(6):698-702. PubMed ID: 7974334
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low-molecular-weight heparin in the treatment of pulmonary embolism.
    Ageno W; Turpie AG
    Semin Vasc Surg; 2000 Sep; 13(3):189-93. PubMed ID: 11005462
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparative double-blind, randomised trial of a new second generation LMWH (bemiparin) and UFH in the prevention of post-operative venous thromboembolism. The Bemiparin Assessment group.
    Kakkar VV; Howes J; Sharma V; Kadziola Z
    Thromb Haemost; 2000 Apr; 83(4):523-9. PubMed ID: 10780310
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dalteparin versus unfractionated heparin in critically ill patients.
    ; Cook D; Meade M; Guyatt G; Walter S; Heels-Ansdell D; Warkentin TE; Zytaruk N; Crowther M; Geerts W; Cooper DJ; Vallance S; Qushmaq I; Rocha M; Berwanger O; Vlahakis NE
    N Engl J Med; 2011 Apr; 364(14):1305-14. PubMed ID: 21417952
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism.
    Büller HR; Davidson BL; Decousus H; Gallus A; Gent M; Piovella F; Prins MH; Raskob G; van den Berg-Segers AE; Cariou R; Leeuwenkamp O; Lensing AW;
    N Engl J Med; 2003 Oct; 349(18):1695-702. PubMed ID: 14585937
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anticoagulation with the low-molecular-weight heparin dalteparin (Fragmin) in atrial fibrillation and TEE-guided cardioversion.
    Bechtold H; Gunzenhauser D; Sawitzki H; Fung S; Janssen D
    Z Kardiol; 2003 Jul; 92(7):532-9. PubMed ID: 12883837
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low-molecular-weight heparin (dalteparin) in women with gynecologic malignancy.
    DeBernardo RL; Perkins RB; Littell RD; Krasner CN; Duska LR
    Obstet Gynecol; 2005 May; 105(5 Pt 1):1006-11. PubMed ID: 15863537
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of lower-dose unfractionated heparin for prophylaxis of deep vein thrombosis and pulmonary embolism in an Asian population.
    Ugaki H; Enomoto T; Fujiwara K; Kimura T; Kawasaki T
    Blood Coagul Fibrinolysis; 2008 Sep; 19(6):585-9. PubMed ID: 18685443
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Subcutaneous adjusted-dose unfractionated heparin vs fixed-dose low-molecular-weight heparin in the initial treatment of venous thromboembolism.
    Prandoni P; Carnovali M; Marchiori A;
    Arch Intern Med; 2004 May; 164(10):1077-83. PubMed ID: 15159264
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevention of fatal pulmonary embolism and mortality in surgical patients: a randomized double-blind comparison of LMWH with unfractionated heparin.
    Haas S; Wolf H; Kakkar AK; Fareed J; Encke A
    Thromb Haemost; 2005 Oct; 94(4):814-9. PubMed ID: 16270636
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low molecular weight heparin administered once versus twice daily in patients with venous thromboembolism: a meta-analysis.
    Couturaud F; Julian JA; Kearon C
    Thromb Haemost; 2001 Oct; 86(4):980-4. PubMed ID: 11686355
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Once-daily subcutaneous dalteparin, a low molecular weight heparin, for the initial treatment of acute deep vein thrombosis.
    Fiessinger JN; Lopez-Fernandez M; Gatterer E; Granqvist S; Kher A; Olsson CG; Söderberg K
    Thromb Haemost; 1996 Aug; 76(2):195-9. PubMed ID: 8865530
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Two daily subcutaneous injections of fragmin as compared with intravenous standard heparin in the treatment of deep venous thrombosis (DVT).
    Bratt G; Aberg W; Johansson M; Törnebohm E; Granqvist S; Lockner D
    Thromb Haemost; 1990 Dec; 64(4):506-10. PubMed ID: 1964751
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mobilization versus immobilization in the treatment of acute proximal deep venous thrombosis: a prospective, randomized, open, multicentre trial.
    Jünger M; Diehm C; Störiko H; Hach-Wunderle V; Heidrich H; Karasch T; Ochs HR; Ranft J; Sannwald GA; Strölin A; Janssen D
    Curr Med Res Opin; 2006 Mar; 22(3):593-602. PubMed ID: 16574042
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of two treatment durations (6 days and 14 days) of a low molecular weight heparin with a 6-day treatment of unfractionated heparin in the initial management of unstable angina or non-Q wave myocardial infarction: FRAX.I.S. (FRAxiparine in Ischaemic Syndrome).
    Eur Heart J; 1999 Nov; 20(21):1553-62. PubMed ID: 10529323
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.